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Abstract

Background

Vancomycin has a complex pharmacokinetic profile and
carries potential risks for nephrotoxicity and ototoxicity. The
pharmacokinetic profile in elderly patients significantly differs
from that of younger patients. It is common practice in many
institutions for pharmacists to intentionally round serum
creatinine levels to 1 mg/dl in elderly patients with levels <1 mg/
dl to avoid overestimating clearance and toxicities. This can
potentially lead to underestimation of creatinine clearance, and
subsequently lead to vancomycin under dosing. The aim of this
study was to evaluate vancomycin target trough attainment
and the time to trough attainment with vancomycin dosing per
pharmacy in elderly patients.

Vancomycin is a glycopeptide antibiotic used to treat drugresistant gram-positive bacteria, including methicillin-resistant
Staphylococcus aureus.(1) It has been a widely used antibiotic
since inception despite its complex pharmacokinetic profile and
carries potential risks for nephrotoxicity and ototoxicity.(2-7) The
vancomycin elimination rate constant and creatinine clearance
have been suggested to be related to age. Additionally, there
remains a sufficient amount of variability in clearance and
volume of distribution observed in elderly patients.(8) Elderly
patients may also have decreased muscle mass, which can lead
to decreases in serum creatinine and affect drug distribution.(9)
It has also been described that serum creatinine production in
elderly patients may be within normal limits, but renal function
may be lower than expected.(10)

Methods
In this retrospective study, patients 75 years and older who
received vancomycin at our institution were evaluated. Subjects
were included in the study if they were at least 75 years of
age, received intravenous vancomycin therapy, and had
a vancomycin trough drawn after the third dose. The study
patients were divided into three serum creatinine groups;
<0.8 mg/dl (LSCr), 0.8-0.9 mg/dl (MSCr), and ≥1 mg/dl (HSCr).
Patients were excluded from the study if they did not meet
inclusion criteria, had no trough levels drawn, or were <75 years
of age.

Results
Two hundred and four patients 75 years or older were included
in the study. The target trough attainment was highest in the
HSCr group (n = 37, 80%), which was significantly higher
than the LSCr (n=21, 31%; p<0.0001) and MSCr (n=42, 46%;
p<0.0001) groups. The time to target trough goals (days, mean
± SD) differed between the three groups, with the LSCr group
taking the longest duration: LSCr: 5.14 ± 2.5; MSCr: 3.74 ± 1.1;
HSCr: 3.78 ± 1.6, p=0.005.

Conclusion
Adjustments need to be done to improve vancomycin dosing
per pharmacy in patients 75 years of age and older. This study
shows that LSCr patients (<0.8 mg/dl) had the lowest rates of
target trough level attainment. Intentionally rounding serum
creatinine to 1 mg/dl if values are less when estimating renal
function in this older patient population may not be predictive
of true renal function and can decrease the likelihood of target
attainment or increase time to target attainment.

In many institutions, pharmacists perform vancomycin dosing,
order serum concentrations for therapeutic drug monitoring,
and adjust the vancomycin dose accordingly based on specific
target trough goals, site of infection, and causative organism.(5)
Despite the clinical evidence that recommends against rounding
serum creatinine when estimating clearance creatinine with
the Cockcroft-Gault method, the practice remains.(9,11-17) Many
institutions, including ours, have pharmacists who utilize serum
creatinine rounding with the Cockcroft-Gault equation.(18-21) A
common practice by the institutional pharmacists is to round up
serum creatinine levels to 1 mg/dl if measured levels are <1 mg/
dl prior to use in creatinine clearance calculations in patients 65
years of age or older. The rationale behind this is to account for
lower muscle mass in the elderly, which can lead to lower serum
creatinine levels and thus potentially an artificially high creatinine
clearance, as previously described above.
National guidance on appropriate dosing of vancomycin in
elderly patients is lacking. The vancomycin guidelines endorsed
by the American Society of Health-System Pharmacists (ASHP),
the Infectious Diseases Society of America (IDSA), and the
Society of Infectious Diseases Pharmacists (SIDP) do not
provide best practices for dosing in older patients.(5) In addition,
published reports pertaining to vancomycin dosing in elderly
patients have been limited. However, a discussion of appropriate
vancomycin dosing in elderly patients was recently started with
Young and colleagues.(22)

Based on the data described above, limited national dosing
guidelines, and the common practice of rounding serum
creatinine to 1 mg/dl in elderly patients with serum creatinine
levels of <1 mg/dl, more clinical data is needed to better
understand the vancomycin utilization in the elderly population.
The aim of this study was to evaluate vancomycin target trough
attainment and the time to target trough attainment with
vancomycin dosing per pharmacy in elderly patients, specifically
in patients 75 years of age or older. We hypothesized that
rounding of serum creatinine to 1 mg/dl in patients with serum
creatinine levels of <1 mg/dl would lead to under dosing as
evident by not achieving trough attainment or increasing time to
trough target attainment.

Methods
St. Joseph Health’s Institutional Review Board approved this
study. In this retrospective study, patients 75 years and older
who received vancomycin at our institution during the time
period of January 1, 2014, to December 31, 2014, were evaluated
for inclusion. All subjects were identified through MeditechTM
Electronic Medical Record reports and pharmacy records. The
study institution is a non-academic community hospital with
325 beds. Subjects were included in the study if they were at
least 75 years of age, received intravenous vancomycin therapy,
and had a vancomycin trough drawn after the third dose. The
study patients were divided into three groups: serum creatinine
<0.8 mg/dl (LSCr), serum creatinine 0.8-0.9 mg/dl (MSCr), and
serum creatinine ≥1 mg/dl (HSCr). The group designation was
based on the value of serum creatinine when vancomycin was
initiated. Only the first occurrence of vancomycin utilization
was included in the study. Patients were excluded from the
study if they did not meet inclusion criteria, had no trough levels
drawn, or were less than 75 years of age. Vancomycin daily
doses were based on the amount of vancomycin received in a
24-hour period. Patient chart reviews were performed to extract
pertinent demographics, laboratory, and clinical data, including
gender, age, height, weight, infection, renal function tests, and
vancomycin dosing and levels.

Statistical Analysis
Descriptive statistics were computed for all study variables that
were measured on an interval or ratio scale. Discrete data were
presented as frequencies and percentages. An independent
student t-test was used to compare mean serum creatinine
values and other continuous variables. The Pearson’s chi-square
or Fisher’s test was used to measure the association between
dichotomous variables. All tests were two-tailed and a P-value
of <0.05 was considered significant. Statistical analyses were
carried out with SPSS version 20.0 (Chicago, IL, USA) and
GraphPad Prism version 6.0 (San Diego, CA, USA).

Results
Two hundred and four patients 75 years of age or older were
identified as receiving vancomycin and a trough level after the
third dose of vancomycin. The patient characteristics (mean ±
SD) include age 85.7 ± 5.98 years, weight 68.6 ± 16.94 kg, and
serum creatinine 1.25 ± 0.78 mg/dl, and consisted of mostly
women, 65% (Table 1). The three serum creatinine groups were
distributed as LSCr (n=67), MSCr (n=91), and HSCr (n=46). The
demographic characteristics are shown in Table 1. The majority
of the differences between the groups were due to the HSCr
group being significantly different from the LSCr and MSCr
groups. The LSCr group had more female subjects (75%) overall,
and shorter (mean ± SD, 63.9 ± 3.7 inches) patients than the
MSCr group (65.6 ± 3.8). The HSCr group had a lower total daily

mg/kg dose of vancomycin (mean ± SD) than the other two
groups (HSCR 15.2 ± 3.3 vs MSCr 18.4 ± 6.2, LSCr 18.5 ± 5.6),
p=0.001. All three groups had more than half of the vancomycin
trough goals set as 15-20 mg/dl and did not differ between the
groups, p=0.148.
The overall vancomycin trough target attainment (Table
1) was highest in the HSCr group (n=37, 80%), which was
significantly higher than the LSCr (n=21, 31%; p<0.0001) and
MSCr (n=42, 46%; p<0.0001) groups. The rates of the 10-15 mg/
dl vancomycin trough target attainment did not statistically differ
between groups, LSCr, n=10 (15%); MSCr, n=23 (25%); HSCr,
n=15 (33%), p=0.0813. The rates of target attainment for the
15-20 mg/dl vancomycin troughs were higher in the HSCr group
(n=22, 48%) compared to the other two groups, LSCr, n=11
(16%); p<0.0001 and MSCr, n=19 (21%); p=0.0003. There were
no significant differences in target trough attainment between
low and high trough levels within each group (data not shown).
The time to target trough goals (days, mean ± SD), differed
between the three groups, LSCr: 5.14 ± 2.5; MSCr: 3.74 ± 1.1;
HSCr: 3.78 ± 1.6, p=0.005. The LSCr group took significantly
longer to reach target trough goals compared to the other two
groups (LSCr vs MSCr, p=0.02 and LSCr vs HSCr, p=0.04).

Discussion
The current ASHP/IDSA /SIDP guidelines on vancomycin
dosing do not address how vancomycin clearance should be
calculated, or how to estimate creatinine clearance. Rather,
the guidelines focus on what troughs or AUC/MIC to target for
specific disease states and toxicity risks with vancomycin.5 This
study evaluated a current practice of vancomycin dosing based
on the knowledge that renal function declines in older patients.
The groups included vancomycin per pharmacy in patients 75
years of age or older and grouped by serum creatinine values
(<0.8 mg/dl [LSCr], serum creatinine 0.8-0.9 mg/dl [MSCr], and
serum creatinine ≥1 mg/dl [HSCr]). The study results show that
the majority of patients were female and on average more than
10 years older than the minimal inclusion age. The mean total
body weights of each patient group did not differ, but the height
of the LSCr group was statistically lower than that of the MSCr
group. Patients with lower serum creatinine (<0.8 mg/dl) had the
lowest rates of vancomycin trough attainment. When examining
trough attainment with the higher trough goal of 15-20 mg/dl, we
found patients with serum creatinine levels <1.0 mg/dl were less
likely to achieve target attainment. In addition to the reduced
rates of target attainment, the time to target trough was longer in
patients with lower serum creatinine levels. The HSCr group had
significantly higher levels of serum creatinine, suggesting true
decreases in renal function, which likely attributed to achieving
the trough goals.
Young and colleagues recently evaluated the impact of rounding
serum creatinine levels to 1 mg/dl to dose vancomycin in
patients ≥65 years of age. The study results suggest that actual
serum creatinine levels may more accurately predict vancomycin
troughs than rounded serum creatinine values.(22) The results
of this study produced similar results to our own, suggesting
older patients with rounded low serum creatinine values did not
achieve vancomycin trough levels as readily as patients with
higher serum creatinine levels, nor is the up-rounded serum
creatinine value indicative of true renal function. Bourguignon
and colleagues evaluated the pharmacokinetics of patients over
the age of 80 years on vancomycin and found that there can be
large inter-individual variability of vancomycin pharmacokinetic
parameters.(8) Additional variabilities in protein binding and
volume of distribution may also account for the differences in
target trough attainment between groups.(23,24) Moreover, the use
of serum creatinine as an estimate of renal function in elderly pa-

tients may not be reliable. Lower serum creatinine levels may
be due to lower body mass, but as seen from our data, renal
function may or may not be decreased. Renal function is thought
to decline with age25, but the extent of renal function decline
is difficult to ascertain. It has been described that one-third
of elderly patients may not have a decline in renal function.26
Because of the variability seen in elderly patients, alternative
strategies need to be considered.
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Limitations
Our study has several limitations. The study is retrospective in
design at a single institution, which limits the assessment to only
the variables collected. This lack of randomization of the three
groups may potentially cause a selection bias. The selection
of serum creatinine cut-off values was arbitrary. Winter and
colleagues similarly evaluated serum creatinine rounding with
a threshold of 0.8 mg/dl and 1 mg/dl for rounding.(17) Evaluating
the groups based on serum creatinine above and below 0.8
mg/dl seemed reasonable. The rationale for the three groups
was to have a single group act as a control group and the other
groups with low-normal levels of creatinine as comparators.
Clinical evidence is scarce when describing vancomycin dosing
in elderly patients with low serum creatinine levels. Vancomycin
dosing is based on variables such as gender, age, weight, and
serum creatinine.(8,11,29,30) In our study, the patients in the LSCr
and MSCr were similar in age, weight, and serum creatinine,
thus allowing for comparisons with the HSCr group. Another
limitation to the study is the potential for variations in clinical
judgement by the clinical pharmacists despite the standardized
protocol for dosing vancomycin. At our institution, only a handful
of the same clinical pharmacists rotate to dose vancomycin as
part of their clinical duties, which may limit some variation but
not all. Lastly, the study did not control for critically ill patients
or collect data on quantitative renal adjustment in various ages.
Critically ill patients generally have different pharmacodynamics
than stable patients.(28)

Conclusions
Adjustments need to be done to improve vancomycin per
pharmacy in patients 75 years of age and older. This study
shows that patients with low serum creatinine <0.8 mg/dl had
the lowest rates of target trough level attainment, specifically for
higher trough goals of 15-20 mg/dl. Use of serum creatinine to
estimate renal function in older patients may not be predictive
of true renal function. Further studies that investigate alternative
dosing strategies with vancomycin need to be explored.
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Table 1. Patient Demographics and Clinical Characteristics

Variables

Age (years), mean ±SD
Female, no. (%)
Height (inches), mean ±SD
Actual body weight (kg), mean ±SD
BUN (mg/dl), mean ±SD

LSCr
SrCR<0.8
(n=67)

MSCr
SrCr 0.8-0.9
(n=91)

HSCr
SrCr≥1
(n=46)

P=value

84.7 ±6.3

84.2 ±5.8

90 ±4.6

0.0001

51 (75)

53 (58)

26 (57)

0.0356

63.9 ±3.7

65.5 ±3.8

64.8 ±4.6

0.036

65 ±17

71.4 ±19

66.8 ±12.8

0.0649

16.4 ±9.1

19.2 ±9.7

45.8 ±29

<0.0001

0.61 ±0.08

0.85 ±0.05

2.08 ±1.28

<0.0001

Medicine floor, no. (%)

45 (67)

63 (69)

22 (48)

0.0375

ICU floor, no. (%)

14 (21)

23 (25)

19 (41)

0.0475

Serum creatinine (mg/dl) mean ±SD
Hospital location

Other, no. (%)

8 (12)

5 (6)

5 (11)

0.3163

18.5 ±5.6

18.4 ±6.2

15.2 ±3.3

0.0024

10-15 mg/dl

22 (33)

42 (46)

15 (33)

0.1480

15-20 mg/dl

45 (67)

49 (54)

31 (67)

0.1480

Vancomycin (mg/kg/d) mean ±SD
Vancomycin trough goals

Figure 1. Rate of Overall Target Trough Attainment by Serum
Creatinine Group
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